Travere Therapeutics Inc. Watch

EX-10.1

from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 5 to Sublicense Agreement

12/34/56

EX-10.1

from 10-Q 2 pages Non-Employee Director Compensation Program

12/34/56

EX-10.32

from 10-K 10 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Fifth Amendment to Trademark License and Supply Agreement

12/34/56

EX-10.30

from 10-K 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential

12/34/56

EX-10.29

from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment One to the Third Amendment to Trademark License and Supply Agreement

12/34/56

EX-10.28

from 10-K 3 pages Third Amendment to Trademark License and Supply Agreement

12/34/56

EX-10.25

from 10-K 15 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Trademark License & Supply Agreement

12/34/56

EX-10.10

from 10-K 4 pages 2024 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan

12/34/56

EX-10.8

from 10-K 2 pages Non-Employee Director Compensation Program

12/34/56

EX-10.2

from 10-Q 30 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Asset Purchase Agreement

12/34/56

EX-10.1

from 8-K 85 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Asset Purchase Agreement by and Between Travere Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. Dated as of July 16, 2023

12/34/56

EX-10.2

from 10-Q 20 pages Employment Agreement

12/34/56

EX-10.39

from 10-K 2 pages Amendment No. 1 to License and Collaboration Agreement

12/34/56

EX-10.37

from 10-K 6 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Master Manufacturing Supply Agreement

12/34/56

EX-10.12

from 10-K 4 pages 2023 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan

12/34/56

EX-10.1

from 8-K/A 20 pages Employment Agreement

12/34/56

EX-10.1

from 10-Q 2 pages Non-Employee Director Compensation Program

12/34/56

EX-10.1

from 8-K 4 pages April 19, 2022 Laura Clague Re: Retirement and Transition Agreement Dear Laura: This Letter Agreement (The “Agreement”) Sets Forth Our Mutual Understanding Regarding Your Planned Retirement as Chief Financial Officer of Travere Therapeutics, Inc., a Delaware Corporation (The “Company”)

12/34/56

EX-10.40

from 10-K 32 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That Travere Therapeutics, Inc. Treats as Private or Confidential. Commercial Supply Agreement

12/34/56

EX-10.27

from 10-K 7 pages Certain Confidential Information Contained in This Document, Marked by […***…], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That Travere Therapeutics, Inc. Treats as Private or Confidential. Amendment No. 4 to Sublicense Agreement

12/34/56